A Pilot Study to Evaluate The Clinical and Immunological Effects of Incorporating a CD40-Agonistic Antibody into the Multimodality Treatment of Resectable Esophageal and GE Junction Cancersrcoma By lsc-webmaster A Pilot Study to Evaluate The Clinical and Immunological Effects of Incorporating a CD40-Agonistic Antibody into the Multimodality Treatment of Resectable Esophageal and GE Junction Cancersrcoma Read More »
A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastatic Melanoma By lsc-webmaster A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastatic Melanoma Read More »
A Phase Ib/II Study of CD40 Agonistic Monoclonal Antibody (APX005M) Together with Gemcitabine and nab-Paclitaxel with or without Nivolumabin Untreated Metastatic Pancreatic Adenocarcinoma Patients By lsc-webmaster A Phase Ib/II Study of CD40 Agonistic Monoclonal Antibody (APX005M) Together with Gemcitabine and nab-Paclitaxel with or without Nivolumabin Untreated Metastatic Pancreatic Adenocarcinoma Patients Read More »
